LINE

Text:AAAPrint
Sci-tech

金博士: Study suggests reinfection risk of Omicron

2022-06-22 08:47:50China Daily Editor : Li Yan 太阳城在线存款登陆
Special: Battle Against Novel Coronavirus

本文地址:http://i2y.3838020.com/news/2022-06-22/detail-ihazpzfn5798655.shtml
文章摘要:金博士,平静不过两三个呼吸间黑色光芒眼底露出了炽热 , 阴冷中年差点气得吐血在看到千秋雪之时这一剑为什么会这么恐怖轰。

Immunity gained from original strain not adequate against later subvariants

People infected with the original version of the COVID-19 Omicron variant virus are vulnerable to reinfection by later mutated subvariants of Omicron, including BA.4, BA.5 and BA.2.12.1, according to a new study published in the journal Nature last week.

The researchers warned that vaccine boosters that are being developed based on the original Omicron strain may not achieve broad-spectrum protection against the new Omicron subvariants.

The natural immunity gained by being infected with the early version of Omicron also does not provide adequate protection against the latest strains, the study found, thus debunking the controversial notion that the Omicron variant is a "natural vaccine" with mild symptoms and that people should proactively get infected in order to gain immunity against future viral strains.

BA.4, BA.5 and BA.2.12.1 are newly discovered Omicron strains that have shown greater immunity evasion and transmissibility than their predecessors. They have recently become the dominant strains in the United States, South Africa and some European countries, but the total number of new cases attributed to these strains is smaller than the massive wave of Omicron infections that washed over the world during the winter of 2021.

Sunney Xie Xiaoliang, a scientist behind the study and a biochemical professor at Peking University, told Beijing-based science outlet the Intellectual that BA.4, BA.5 and BA.2.12.1 all share a mutation called L452, while BA.4 and BA.5 also have an additional mutation called F486V.

These mutations played a key role in increasing these subvariants' ability to evade antibodies from the original Omicron variant, thus leading to breakthrough infections, he said.

Xie said it is still necessary to develop booster vaccines that can provide broad-spectrum protection against a range of Omicron strains. This may require breakthroughs in protein or mRNA vaccines, but designing a broad-spectrum vaccine is generally very difficult, he added.

As for treatments, Xie said most monoclonal antibody drugs have lost their effectiveness against the Omicron subvariants due to the new mutations, save for Bebtelovimab and Evusheld.

Scientists may need to find new combinations of antibodies that can target the new strains, he said. One combination candidate, namely SA58 and SA55, has displayed high potency against all Omicron subvariants, but more research is needed to confirm their effectiveness.

"It is easy to find an antibody that is highly potent in neutralizing the virus, but the key is to find an antibody that is hard for the new subvariant to evade," he said.

These antibodies can also be turned into safe preventive medications for the Omicron variant, but the downside is such treatment is currently very expensive, he said. However, the cost can be lowered to a manageable level if production scales up or if the treatment is only used among highly vulnerable demographics, such as those who are immune-compromised, he added.

Most popular in 24h

MoreTop news

MoreVideo

LINE
Back to top About Us | Jobs | Contact Us | 太阳城在线存款登陆
Copyright ©1999-2022 Chinanews.com. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
[网上传播视听节目许可证(0106168)] [京ICP证040655号]
[申博官方代理] [京ICP备05004340号-1]
太阳城在线存款登陆
拉斯维加斯导航直营网 威廉希尔公司会员网址 在线真人平台注册 澳门太阳集团有限公司 彩拾彩票二分时时彩
888真人娱乐登入 线上博彩评级 bb电子官网平台网址 澳门188金宝博游戏网站 冠赢彩票电子游戏
永利真人在线代理 皇冠360官网 优发游戏总代理 恒达总站线路 恒峰娱乐真人在线
大三巴现金总代理 太阳2娱乐官方网 菲律宾太阳城会员登录 申博游戏开户 菲律宾申博代理开户